Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center

Table 1 Demographic and clinical features, n (%)

Feature	n = 38
Age at diagnosis (years)
Median (min-max)	52 (24-77)
Sex
Female	21 (55.3)
Male	17 (44.7)
Region of birth
Lima	14 (36.8)
Huánuco	5 (13.2)
Ancash	3 (7.9)
Ica	3 (7.9)
Junín	3 (7.9)
Lambayeque	2 (5.3)
Ayacucho	2 (5.3)
Cajamarca	2 (5.3)
Amazonas	1 (2.6)
Cusco	1 (2.6)
Puno	1 (2.6)
Tacna	1 (2.6)
BMI, kg/m2
Median (IQR)	23.438 (20.65-26.279)
ECOG scale
0	1 (2.6)
1	35 (92.1)
2	2 (5.3)
Symptoms
Abdominal pain	31 (81.6)
Rectal bleeding	12 (31.6)
Weight loss	9 (23.7)
Diarrhea	5 (13.2)
Emesis	4 (10.5)
Flushing	2 (5.3)

IQR: Interquartile range; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group.

Table 2 Systemic therapy, n (%)

Feature	n = 38
First-line treatment
Temozolomide/capecitabine	35 (92.1)
CAPOX	1 (2.6)
Cisplatin/etoposide	1 (2.6)
Interferon alpha	1 (2.6)
First-line cycles
Median (IQR)	9 (6-22.75)
Duration of first-line treatment, days
Median (IQR)	331 (133.25-606)
Second-line treatment
Yes	14 (36.8)
No	24 (63.2)
Second-line regimen, n = 14
Capecitabine	4 (28.6)
CAPOX	3 (21.4)
TEMCAP	3 (21.4)
Cisplatin/etoposide	1 (7.1)
Dacarbazine (DTIC)	1 (7.1)
GEMOX	1 (7.1)
Temozolomide	1 (7.1)

IQR: Interquartile range; TEMCAP: Temozolomide and capecitabine regimen; CAPOX: capecitabine/oxaliplatin; GEMOX: gemcitabine/oxaliplatin.

Table 3 Adverse events during chemotherapy by grade, n (%)

	Grade
	1	2	3	4
Neutropenia	3 (7.9)	1 (2.6)	2 (5.3)	1 (2.6)
Hand-foot syndrome	5 (13.2)	1 (2.6)
Hypertransaminasemia	3 (7.9)	2 (5.3)
Nausea	4 (10.5)		1 (2.6)
Peripheral neuropathy	4 (10.5)	1 (2.6)
Vomiting	4 (10.5)	1 (2.6)
Anemia	2 (5.3)		1 (2.6)	1 (2.6)
Asthenia	4 (10.5)
Constipation	4 (10.5)
Thrombocytopenia			2 (5.3)	2 (5.3)
Anorexia	3 (7.9)
Diarrhea	2 (5.3)
Sialorrhea	2 (5.3)
Hyperbilirubinemia	1 (2.6)